Search results for: congestive heart failure

Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis

February 18, 2021 • By Carina Stanton

Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.... [Read More]

Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients

February 16, 2021 • By Susan Bernstein

In a controlled, large-cohort, longitudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1 This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the… [Read More]

Autoimmune Inflammation Increases Risk of Heart Disease

January 19, 2018 • By Susan Bernstein

SAN DIEGO—It’s no secret: Autoimmune, inflammatory rheumatic disease raises a patient’s risk of cardiovascular disease (CVD). “Inflammation may affect all aspects of the cardiac structure and function,” said Rekha Mankad, MD, FACC, director of the Women’s Heart Clinic at the Mayo Clinic in Rochester, Minn. Dr. Mankad also oversees a cardio-rheumatology clinic to assess and treat… [Read More]

2014 ACR/ARHP Annual Meeting: Diagnosis, Management of Sarcoidosis in the Heart, Central Nervous System

March 1, 2015 • By Kathy Holliman

Without reliable diagnostic tests or evidence-based treatment guidelines, patient symptoms critical to diagnosing disease... [Read More]

The Heart-SCC Puzzle

May 1, 2009 • By Olga Kaloudi, MD, and Marco Matucci Cerinic, MD, PhD

Identifying and treating cardiac involvement in systemic sclerosis can be a challenge... [Read More]

Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap

February 16, 2021 • By Mohammad A. Ursani, MD, RhMSUS, Ojas Naik, MD, Rohaan Khan & William F. Glass II, MD, PhD

Drug-induced lupus erythematosus and ANCA-associated vasculitis (AAV) are both autoimmune conditions associated with the use of hydralazine, a commonly prescribed drug for hypertension and congestive heart failure. Although the pathogenesis is unknown, it is believed that hydralazine alters neutrophil and lymphocyte function and promotes exposure of antigens, leading to the development of anti-neutrophil antibodies (ANCA)… [Read More]

The History of ACE Inhibitors in Scleroderma Renal Crisis

February 16, 2021 • By Ruth Jessen Hickman, MD

Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler… [Read More]

ACR Introduces Draft Guideline for RA Management

November 23, 2020 • By Jason Liebowitz, MD

Treating RA can be complicated, especially if the patient is suffering from comorbidities. In a session at ACR Convergence 2020, experts discussed the development of a new ACR draft guideline for RA management & how it can be applied in real-life clinical practice.... [Read More]

The Doctor Will See You Now: Legal & Regulatory Reforms Expand Telemedicine

March 17, 2020 • By Steven M. Harris, Esq.

In this time of COVID-19, you may be considering ways to deliver routine rheumatologic care via some form of telemedicine. Here are some of the legal considerations.... [Read More]

Learn to Navigate the Seas of Uncertainty in Rheumatology Training

August 16, 2019 • By Richard Zamore, MD, MPH

Rheumatology is a field rife with uncertainty. With regard to both diagnosis and treatment, we live in a world of rare diseases that are difficult to study. As a result, we are often left without an answer to our diagnostic dilemmas and without clarity when deciding the best treatment options for our patients. For rheumatologists… [Read More]